Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment

Evaluation committee members

This topic was considered as a cost comparison evaluation by the chair and vice chair of committee C.

Committee members are asked to declare any interests in the technology being evaluated. If it is considered there is a conflict of interest, the member is excluded from participating further in that evaluation.

Chair

James Fotheringham
Chair, technology appraisal committee C

Vice chair

Richard Nicholas
Vice chair, technology appraisal committee C

NICE project team

Each evaluation is assigned to a team consisting of 1 or more health technology analysts (who act as technical leads for the evaluation), a technical adviser, a project manager, and an associate director or principal technical adviser.

Madiha Adam
Technical lead

Claire Hawksworth and Emily Leckenby
Technical advisers

Leena Issa
Project manager

Lorna Dunning
Associate director

ISBN: 978-1-4731-9536-3